B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I Manufacturers/sponsors:

Amgen

II Professional/specialist and patient/carer groups:

Breakthrough Breast Cancer

Breast Cancer Care

Macmillan Cancer Support

Prostate Cancer Support Federation

British Orthopaedic Oncology Society

British Prostate Group

British Psychosocial Oncology Society

British Society for Haematology

British Uro-Oncology Group

Cancer Research UK

Royal College of Nursing

Royal College of Physicians

III Other consultees:

Department of Health

Welsh Government

IV Commentator organisations (without the right of appeal):

British National Formulary

Commissioning Support Appraisals Services

Department of Health, Social Services and Public Safety for Northern Ireland

Healthcare Improvement Scotland

Novartis

British Prostate Group

MRC Clinical Trials Unit

Prostate Action

Aberdeen Health Technology Assessment Group

National Institute for Health Research Health Technology Assessment Programme

National Collaborating Centre for Cancer

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on Denosumab for the treatment of bone metastases from solid tumours by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

D Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.